Reza Fathi - Redhill Biopharma Senior Development
| RDHL Stock | USD 7.80 1.02 15.04% |
Executive
Dr. Reza Fathi serves as Senior Vice President Research Development at Redhill Biopharma Ltd, effective since May 1, 2010. His work experience includes the following roles Director of Research in XTL Biopharmaceuticals Inc., Director of Research at Vivoquest, Inc., Manager of Chemical Biology Research at the Institute of Chemistry and Chemical Biology at Harvard Medical School and Head of Discovery Group at PharmaGenics, Inc. since 2010.
| Age | 69 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Address | 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921 |
| Phone | 972 3 541 3131 |
| Web | https://www.redhillbio.com |
Redhill Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.4488) % which means that it has lost $0.4488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.0861) %, meaning that it created substantial loss on money invested by shareholders. Redhill Biopharma's management efficiency ratios could be used to measure how well Redhill Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 1.44 this year. Return On Capital Employed is expected to rise to 3.49 this year. At this time, Redhill Biopharma's Other Assets are quite stable compared to the past year. Return On Tangible Assets is expected to rise to 1.44 this year, although the value of Other Current Assets will most likely fall to about 2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| MBA MD | Aquestive Therapeutics | 66 | |
| Ernest Toth | Aquestive Therapeutics | 65 | |
| MD FAAFP | Collegium Pharmaceutical | 63 | |
| DMD MD | Evoke Pharma | 76 | |
| Kara Morley | Lifecore Biomedical | N/A | |
| Rita Keynan | Painreform | 55 | |
| Steve Laninga | Lifecore Biomedical | N/A | |
| John Shulman | Petros Pharmaceuticals | 61 | |
| Cassie Jung | Aquestive Therapeutics | 45 | |
| Brikkelle Thompson | Lifecore Biomedical | N/A | |
| Todd Anthony | Cumberland Pharmaceuticals | 63 | |
| Darren Hieber | Lifecore Biomedical | N/A | |
| Huang CFA | China Pharma Holdings | N/A | |
| John Hamm | Cumberland Pharmaceuticals | 68 | |
| Lori McKenna | Cyclo Therapeutics | N/A | |
| Matt Augustson | Lifecore Biomedical | N/A | |
| Sherry Korczynski | Aquestive Therapeutics | N/A | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
| Erin Gull | Cumberland Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -17.09 | ||||
| Return On Asset | -0.45 |
Redhill Biopharma Leadership Team
Elected by the shareholders, the Redhill Biopharma's board of directors comprises two types of representatives: Redhill Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Redhill. The board's role is to monitor Redhill Biopharma's management team and ensure that shareholders' interests are well served. Redhill Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Redhill Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Reza Fathi, Senior Development | ||
| Kristin Comer, G VP | ||
| Valerie Graceffa, VP Sales | ||
| Razi Ingber, Chief Officer | ||
| Dror BenAsher, Chairman of the Board, CEO | ||
| Rick Scruggs, President Officer | ||
| Rob Jackson, VP Marketing | ||
| Adi Frish, Sr. VP of Bus. Devel. and Licensing | ||
| Micha BenChorin, Chief Officer | ||
| Patricia RAC, Senior Affairs | ||
| MSc MPhil, Chief Officer | ||
| FACP MD, Chief Officer | ||
| Guy Goldberg, Chief Business Officer | ||
| Alexandra Okmian, Senior Manager | ||
| Guy JD, Chief Officer |
Redhill Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Redhill Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.09 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (3.28) % | ||||
| Current Valuation | 3.27 M | ||||
| Shares Outstanding | 1.28 M | ||||
| Shares Owned By Institutions | 5.90 % | ||||
| Number Of Shares Shorted | 1.56 K | ||||
| Price To Earning | (3.67) X | ||||
| Price To Book | 163.74 X | ||||
| Price To Sales | 2.69 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share 4.733 | Quarterly Revenue Growth (0.28) | Return On Assets (0.45) | Return On Equity (17.09) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.